Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection

Anne C. Moore, Emery G. Dora, Nadine Peinovich, Kiersten P. Tucker, Karen Lin, Mario Cortese, Sean N. Tucker
doi: https://doi.org/10.1101/2020.09.04.283853
Anne C. Moore
1School of Biochemistry and Cell Biology, University College Cork, Cork, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emery G. Dora
2Vaxart, Inc. South San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nadine Peinovich
2Vaxart, Inc. South San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kiersten P. Tucker
2Vaxart, Inc. South San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen Lin
2Vaxart, Inc. South San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mario Cortese
2Vaxart, Inc. South San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sean N. Tucker
2Vaxart, Inc. South San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: stucker@vaxart.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Preview PDF
Loading

SUMMARY

There is an urgent need to develop efficacious vaccines against SARS-CoV-2 that also address the issues of deployment, equitable access, and vaccine acceptance. Ideally, the vaccine would prevent virus infection and transmission as well as preventing COVID-19 disease. We previously developed an oral adenovirus-based vaccine technology that induces both mucosal and systemic immunity in humans. Here we investigate the immunogenicity of a range of candidate adenovirusbased vaccines, expressing full or partial sequences of the spike and nucleocapsid proteins, in mice. We demonstrate that, compared to expression of the S1 domain or a stabilized spike antigen, the full length, wild-type spike antigen induces significantly higher neutralizing antibodies in the periphery and in the lungs, when the vaccine is administered mucosally. Antigen-specific CD4+ and CD8+ T cells were induced by this leading vaccine candidate at low and high doses. This fulllength spike antigen plus nucleocapsid adenovirus construct has been prioritized for further clinical development.

Competing Interest Statement

EGD, ND, KPT, KLM MC and SNT are current employees and/or own stock options in Vaxart, the sponsor of the studies. EGD and SNT are named as inventors covering a SARS-CoV-2 (nCoV-19) vaccine. SNT is named as an inventor on patents covering the vaccine platform. ACM declares no competing interest.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted September 06, 2020.
Download PDF

Supplementary Material

Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection
Anne C. Moore, Emery G. Dora, Nadine Peinovich, Kiersten P. Tucker, Karen Lin, Mario Cortese, Sean N. Tucker
bioRxiv 2020.09.04.283853; doi: https://doi.org/10.1101/2020.09.04.283853
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection
Anne C. Moore, Emery G. Dora, Nadine Peinovich, Kiersten P. Tucker, Karen Lin, Mario Cortese, Sean N. Tucker
bioRxiv 2020.09.04.283853; doi: https://doi.org/10.1101/2020.09.04.283853

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Immunology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4229)
  • Biochemistry (9118)
  • Bioengineering (6753)
  • Bioinformatics (23947)
  • Biophysics (12103)
  • Cancer Biology (9498)
  • Cell Biology (13745)
  • Clinical Trials (138)
  • Developmental Biology (7617)
  • Ecology (11664)
  • Epidemiology (2066)
  • Evolutionary Biology (15479)
  • Genetics (10621)
  • Genomics (14297)
  • Immunology (9467)
  • Microbiology (22806)
  • Molecular Biology (9081)
  • Neuroscience (48895)
  • Paleontology (355)
  • Pathology (1479)
  • Pharmacology and Toxicology (2566)
  • Physiology (3826)
  • Plant Biology (8309)
  • Scientific Communication and Education (1467)
  • Synthetic Biology (2294)
  • Systems Biology (6172)
  • Zoology (1297)